Community

Our community narratives are driven by numbers and valuation.

Value any stock for free in seconds

Get alerts and valuation updates

Participate in discussions

Weekly Picks

RenovoRx

Stock_Research_Today

Community Contributor

Revolutionizing Cancer Treatment

A Precision Approach to Hard-to-Treat Cancers RenovoRx, Inc. (Nasdaq: RNXT), based in Mountain View, California, is a clinical-stage biopharma company taking a new approach to cancer treatment.

View narrative

US$4.20

73.6% undervalued

371.30%

Revenue growth p.a.

17 days ago

Apple

Investingwilly

Community Contributor

Apple: A Dying Star with an Overpriced Valuation

Intro Apple Inc. (AAPL) has long been one of the most beloved stocks in the market, celebrated for its sleek products and loyal customer base.

View narrative

US$177.34

19.2% overvalued

14.68%

Revenue growth p.a.

2 days ago

Avino Silver & Gold Mines

Agricola

Community Contributor

Avino a case for USD$20 per share within 5 years (assuming $3,500 gold, $100 silver and $4 copper).

Full disclosure. I am a shareholder at the time of writing this.

View narrative

CA$26.79

86.0% undervalued

78.01%

Revenue growth p.a.

17 days ago

RENK Group

Chris1

Community Contributor

Riding the Defense Boom RENK Sees Revenue Climb at 15% CAGR by FY 2029

In a renewed political landscape where a Trump administration adopts a more interventionist stance toward Ukraine, the United States sharply increases its military aid—providing advanced tank transmissions, power packs, and suspension systems. This pivot alleviates initial concerns among European allies, but it simultaneously reinforces the imperative for Europe to shore up its own defense capabilities.

View narrative

€69.87

20.5% undervalued

15.00%

Revenue growth p.a.

18 days ago

Load previous narratives

Splash Beverage Group

AnalystConsensusTarget

Consensus Narrative from Analysts

Will Expand US Distribution And Acquire Energy Drink Brand

Key Takeaways Expansion in key U.S. regions, strategic retail partnerships, and new product offerings are set to drive significant revenue growth for Splash Beverage Group. Investment in high-margin businesses like Qplash and energy drinks is likely to enhance cash flow and boost operational efficiency.

View narrative

US$40.00

86.9% undervalued

60.14%

Revenue growth p.a.

15 days ago

Rivalry

AnalystConsensusTarget

Consensus Narrative from Analysts

Digital Rebrand And NUTZ Token Will Attract High-Value Gambling Users

Key Takeaways Crypto integration and a digital-first rebrand are expected to boost user engagement, revenue, and customer loyalty. Significant expense reduction and VIP program development set the stage for near-term profitability and stable cash flow.

View narrative

CA$0.50

90.0% undervalued

47.66%

Revenue growth p.a.

15 days ago

LifeSpeak

AnalystConsensusTarget

Consensus Narrative from 2 Analysts

GreenShield And Allstate Deals Will Drive Operational Success

Key Takeaways Strategic partnerships and new clients like GreenShield and Allstate are expected to drive revenue and earnings growth through enhanced revenue streams. Focus on high-margin deals and operational efficiencies could improve net margins and provide earnings stability despite market headwinds.

View narrative

CA$0.38

17.1% undervalued

7.14%

Revenue growth p.a.

15 days ago

Air Industries Group

AnalystConsensusTarget

Consensus Narrative from 1 Analyst

New Aircraft Contracts And Facility Investments Will Expand Production Capacity

Key Takeaways Strong future revenue growth anticipated due to improved book-to-bill ratio and increased backlog. Investment in efficiency and military program alignment could boost margins and stabilize earnings amidst defense budget challenges.

View narrative

US$6.50

50.3% undervalued

4.23%

Revenue growth p.a.

15 days ago

TeraGo

AnalystConsensusTarget

Consensus Narrative from 1 Analyst

Flexible Millimeter Wave Use Will Unlock Mobile Opportunities

Key Takeaways TERAGO's strategic mid-market focus and reduced churn anticipate future revenue growth, bolstered by improved account revenues and spectral assets. Enhanced operational and financial results, including EBITDA growth and increased cash flow, suggest stronger net margins and earnings potential.

View narrative

CA$2.60

55.8% undervalued

4.11%

Revenue growth p.a.

15 days ago

Biovica International

AnalystConsensusTarget

Consensus Narrative from 2 Analysts

DiviTum Entry Will Expand Breast Cancer Treatment Opportunities

Key Takeaways Biovica's strategic partnerships and agreements are expected to expand market penetration, potentially boosting sales and future revenue growth. New clinical trial data and collaborations may enhance adoption of DiviTum, improving revenue streams and profit margins.

View narrative

SEK 2.05

56.7% undervalued

226.03%

Revenue growth p.a.

15 days ago

Aterian

AnalystConsensusTarget

Consensus Narrative from Analysts

Target Plus, Amazon And UK Entry Will Shape Future Success

Key Takeaways Aterian plans strategic market and product expansion to boost revenue and margins through new channels, consumable products, and Amazon partnerships. Supply chain diversification and technological advancements aim to enhance cost efficiency and support long-term earnings growth, supplemented by a share buyback program.

View narrative

US$8.00

77.9% undervalued

2.44%

Revenue growth p.a.

15 days ago

BioXcel Therapeutics

AnalystConsensusTarget

Consensus Narrative from 3 Analysts

BXCL501 And SERENITY Trials Will Unlock New Treatment Horizons

Key Takeaways Advancing Phase III trials and successful SERENITY outcomes could expand market access and boost revenue through FDA approvals and new partnerships. Cost reduction initiatives and strategic financing strengthen financial stability, improving margins and enabling further commercialization efforts.

View narrative

US$36.25

96.0% undervalued

198.06%

Revenue growth p.a.

15 days ago

NextEd Group

AnalystConsensusTarget

Consensus Narrative from 2 Analysts

Expanding High-Demand Courses Will Strengthen Future Position

Key Takeaways Focus on higher-margin courses and efficient campus utilization is expected to boost revenue and stabilize margins. Expanding in-demand course offerings aligns with trends, potentially enhancing future revenue streams and market position.

View narrative

AU$0.33

63.1% undervalued

3.46%

Revenue growth p.a.

15 days ago

Community

Weekly Picks

Revolutionizing Cancer Treatment

Apple: A Dying Star with an Overpriced Valuation

Avino a case for USD$20 per share within 5 years (assuming $3,500 gold, $100 silver and $4 copper).

Riding the Defense Boom RENK Sees Revenue Climb at 15% CAGR by FY 2029

Will Expand US Distribution And Acquire Energy Drink Brand

Digital Rebrand And NUTZ Token Will Attract High-Value Gambling Users

GreenShield And Allstate Deals Will Drive Operational Success

New Aircraft Contracts And Facility Investments Will Expand Production Capacity

Flexible Millimeter Wave Use Will Unlock Mobile Opportunities

DiviTum Entry Will Expand Breast Cancer Treatment Opportunities

Target Plus, Amazon And UK Entry Will Shape Future Success

BXCL501 And SERENITY Trials Will Unlock New Treatment Horizons

Expanding High-Demand Courses Will Strengthen Future Position

Value any company in seconds

Popular companies

Community

Weekly Picks

Revolutionizing Cancer Treatment

Apple: A Dying Star with an Overpriced Valuation

Avino a case for USD$20 per share within 5 years (assuming $3,500 gold, $100 silver and $4 copper).

Riding the Defense Boom RENK Sees Revenue Climb at 15% CAGR by FY 2029

Community Investing Ideas

Will Expand US Distribution And Acquire Energy Drink Brand

Digital Rebrand And NUTZ Token Will Attract High-Value Gambling Users

GreenShield And Allstate Deals Will Drive Operational Success

New Aircraft Contracts And Facility Investments Will Expand Production Capacity

Flexible Millimeter Wave Use Will Unlock Mobile Opportunities

DiviTum Entry Will Expand Breast Cancer Treatment Opportunities

Target Plus, Amazon And UK Entry Will Shape Future Success

BXCL501 And SERENITY Trials Will Unlock New Treatment Horizons

Expanding High-Demand Courses Will Strengthen Future Position

Value any company in seconds

Popular companies